Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SMO

SMO

Brief Information

Name:Smoothened receptor
Target Synonym:SMO,SMOH,Smoothened, Frizzled Class Receptor,Smoothened, Frizzled Family Receptor,Frizzled Family Member 11,Protein Gx,Seven Transmembrane Helix Receptor,Smoothened Homolog (Drosophila),Smoothened Homolog,FZD11,CRJS,Gx,Smoothened Receptor,Smoothened, Seven Transmembrane Spanning Receptor,Smoothened (Drosophila) Homolog
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SMO-H52P3 Human Human SMO Full Length Protein (VLP)
ACRO Quality

Part of Bioactivity data

SMO-H52P3-MALS-HPLC
 SMO ELISA

Immobilized Human SMO Full Length Protein-VLP (Cat. No. SMO-H52P3) at 10 μg/mL (100 μL/well) can bind Anti-SMO antibody with a linear range of 0.01-2.5 μg/mL (QC tested).

Synonym Name

SMO,smoothened, frizzled class receptor,CRJS, FZD11, Gx, PHLS, SMOH

Background

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Glasdegib PF-04; PF-4449913; PF-04449913 Approved Pfizer Pharmaceuticals Ltd (China) Daurismo United States Leukemia, Myeloid, Acute Pfizer Inc 2018-11-21 Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Kidney Diseases; Hepatic Insufficiency; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Fasciitis Details
Vismodegib R-3616; RG-3616; GDC-0449 Approved Genentech Inc, F. Hoffmann-La Roche Ltd Erivedge United States Carcinoma, Basal Cell Genentech Inc 2012-01-30 Colorectal Neoplasms; Chondrosarcoma, Clear Cell; Multiple Myeloma; Basal Cell Nevus Syndrome; Neurofibrosarcoma; Sarcoma; Breast Neoplasms; Osteosarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Brain Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Gliosarcoma; Liposarcoma; Gastrointestinal Stromal Tumors; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Leukemia, Myeloid, Acute; Uterine Neoplasms; Chondrosarcoma, Mesenchymal; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma; Sarcoma, Kaposi; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Hemangioendothelioma, Epithelioid; Stomach Neoplasms; Leiomyosarcoma; Rhabdomyosarcoma; Medulloblastoma; Ovarian Neoplasms; Chondrosarcoma; Fibrosarcoma; Carcinoma, Basal Cell; Hemangiosarcoma; Desmoplastic Small Round Cell Tumor; Mesenchymoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Solid tumours; Odontogenic Cyst, Calcifying; Graft vs Host Disease; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Glioblastoma; Pancre Details
Sonidegib Diphosphate LDE-225; NVP-LDE-225 Approved Novartis Pharma Ag Odomzo, 奥昔朵 United States Carcinoma, Basal Cell Sun Pharmaceutical Industries Ltd 2015-07-24 Colorectal Neoplasms; Glioblastoma; Myeloproliferative Disorders; Blood Platelet Disorders; Multiple Myeloma; Basal Cell Nevus Syndrome; Prostatic Neoplasms; Breast Neoplasms; Neuroblastoma; Thrombocytosis; Primary Myelofibrosis; Pancreatic Neoplasms; Astrocytoma; Hepatic Insufficiency; Bone Marrow Diseases; Carcinoma, Pancreatic Ductal; Leukemia, Myeloid, Acute; Lung Neoplasms; Glioma; Carcinoma, Hepatocellular; Thrombocythemia, Essential; Adenocarcinoma; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours; Hematologic Neoplasms; Rhabdomyosarcoma; Leukemia; Medulloblastoma; Blood Coagulation Disorders; Hemorrhagic Disorders; Hematologic Diseases; Leukemia, Myelogenous, Chronic; Bone Marrow Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Hepatoblastoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Fibrosis; Skin Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ZSP-1602 ZSP-1602 Phase 1 Clinical Guangdong Zhongsheng Pharmaceutical Co Ltd Medulloblastoma; Carcinoma; Carcinoma, Basal Cell; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Neuroendocrine Tumors; Glioma; Adenocarcinoma Details
Patidegib SGT-610; BBP-009; FIN-5; IPI-926 Phase 3 Clinical Infinity Pharmaceuticals Inc Chondrosarcoma; Head and Neck Neoplasms; Carcinoma, Basal Cell; Neoplasms; Pancreatic Neoplasms; Basal Cell Nevus Syndrome; Primary Myelofibrosis; Adenocarcinoma Details
Taladegib RXDX-109; ENV-IPF-101; ENV-ONC-101; LY-2940680; ENV-101 Phase 2 Clinical Eli Lilly And Company Solid tumours; Medulloblastoma; Rhabdomyosarcoma; Idiopathic Pulmonary Fibrosis; Colonic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Cholangiocarcinoma; Sarcoma; Breast Neoplasms; Neoplasm Metastasis Details
Cipromedegib SHR-1539 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details
GT-1708F GT-1708; GT1708F; GT-1708F Phase 2 Clinical Suzhou Koshine Biomedica Inc Hematologic Neoplasms; Solid tumours; Idiopathic Pulmonary Fibrosis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message